靶向Brachyury（一种与肿瘤上皮-间质转化相关的转录因子）的癌症疫苗的研发
Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.
作者信息
Hamilton Duane H, David Justin M, Dominguez Charli, Palena Claudia
机构信息
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Cells Tissues Organs. 2017;203(2):128-138. doi: 10.1159/000446495. Epub 2017 Feb 20.
Abstract
Epithelial-mesenchymal transition (EMT) is recognized as a relevant process during the progression of carcinomas towards metastatic disease. Epithelial cancer cells undergoing an EMT program may acquire mesenchymal features, motility, invasiveness, and resistance to a variety of anticancer therapeutics. Preventing or reverting the EMT process in carcinomas has the potential to minimize tumor dissemination and the emergence of therapeutic resistance. One of the strategies currently under investigation to target tumor cells undergoing EMT is the generation of a sustained immune response directed against an essential molecular driver of the process. This review focuses on the current development of immune-mediated anticancer interventions aimed at targeting a transcription factor, brachyury, associated with human tumor EMT. Also presented here is a summary of recent studies demonstrating a role for EMT in tumor resistance to immune effector cytotoxicity, and the study of novel strategies aimed at reverting the EMT to be used in combination with immune-mediated anticancer interventions.
摘要
上皮-间质转化（EMT）被认为是癌症向转移性疾病进展过程中的一个相关过程。经历EMT程序的上皮癌细胞可能获得间质特征、运动性、侵袭性以及对多种抗癌治疗的抗性。在癌症中预防或逆转EMT过程有可能将肿瘤扩散和治疗抗性的出现降至最低。目前正在研究的针对经历EMT的肿瘤细胞的策略之一是产生针对该过程的关键分子驱动因子的持续免疫反应。本综述聚焦于旨在靶向与人类肿瘤EMT相关的转录因子短尾相关蛋白的免疫介导抗癌干预措施的当前进展。本文还总结了最近的研究，这些研究证明了EMT在肿瘤对免疫效应细胞毒性的抗性中的作用，以及旨在逆转EMT以与免疫介导的抗癌干预措施联合使用的新策略的研究。
相似文献
1
Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.靶向Brachyury（一种与肿瘤上皮-间质转化相关的转录因子）的癌症疫苗的研发
Cells Tissues Organs. 2017;203(2):128-138. doi: 10.1159/000446495. Epub 2017 Feb 20.
2
Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.通过基于Brachyury的疫苗对肿瘤上皮-间质转化进行免疫靶向治疗。
Adv Cancer Res. 2015;128:69-93. doi: 10.1016/bs.acr.2015.04.001. Epub 2015 May 12.
3
Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.针对上皮-间质转化的癌症疫苗：Brachyury 及其他驱动癌的间充质样表型的因素的组织分布。
Semin Oncol. 2012 Jun;39(3):358-66. doi: 10.1053/j.seminoncol.2012.02.005.
4
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.通过重组短尾蝾螈-酵母疫苗对经历上皮-间质转化的肿瘤细胞进行免疫靶向治疗。
Oncotarget. 2013 Oct;4(10):1777-90. doi: 10.18632/oncotarget.1295.
5
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.针对转录因子 Brachyury 的痘病毒 TRICOM 基疫苗的 I 期研究。
Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.
6
Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.鉴定和表征短尾蛋白的细胞毒性T淋巴细胞激动剂表位，短尾蛋白是一种参与上皮-间质转化和转移的转录因子。
Cancer Immunol Immunother. 2014 Dec;63(12):1307-17. doi: 10.1007/s00262-014-1603-2. Epub 2014 Sep 4.
7
An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype.转化生长因子-β1（TGF-β1）与转录因子 brachyury 之间的自分泌环控制着人癌细胞向间充质表型的转变。
Mol Cancer Ther. 2013 Sep;12(9):1805-15. doi: 10.1158/1535-7163.MCT-12-1007. Epub 2013 Jun 19.
8
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.人类T盒中胚层转录因子Brachyury是T细胞介导的癌症免疫疗法的候选靶点。
Clin Cancer Res. 2007 Apr 15;13(8):2471-8. doi: 10.1158/1078-0432.CCR-06-2353.
9
Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.短尾蛋白，一种疫苗靶点，在三阴性乳腺癌中过度表达。
Endocr Relat Cancer. 2016 Oct;23(10):783-796. doi: 10.1530/ERC-16-0037.
10
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.Brachyury 是上皮-间充质转化的驱动因子，在人类肺肿瘤中过表达：这为针对肺癌的新型干预提供了机会。
Clin Cancer Res. 2012 Jul 15;18(14):3868-79. doi: 10.1158/1078-0432.CCR-11-3211. Epub 2012 May 18.
引用本文的文献
1
A single-cell and tissue-scale analysis suite resolves Mixl1's role in heart development.一个单细胞和组织尺度分析套件解析了Mixl1在心脏发育中的作用。
iScience. 2025 Apr 10;28(5):112397. doi: 10.1016/j.isci.2025.112397. eCollection 2025 May 16.
2
Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.口腔鳞状细胞癌手术前后血浆无细胞 DNA 甲基组分析。
Mol Carcinog. 2023 Apr;62(4):493-502. doi: 10.1002/mc.23501. Epub 2023 Jan 13.
3
Knockdown of Brachyury Suppresses Breast Cancer Cell Proliferation and Migration via Targeting E2F3.敲低Brachyury通过靶向E2F3抑制乳腺癌细胞增殖和迁移。
J Oncol. 2022 Nov 22;2022:7913067. doi: 10.1155/2022/7913067. eCollection 2022.
4
Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes.基因表达谱分析鉴定出两种与不同分子机制和临床结局相关的脊索瘤亚型。
Clin Cancer Res. 2023 Jan 4;29(1):261-270. doi: 10.1158/1078-0432.CCR-22-1865.
5
Chordoma-Current Understanding and Modern Treatment Paradigms.脊索瘤——当前的认识与现代治疗模式
J Clin Med. 2021 Mar 4;10(5):1054. doi: 10.3390/jcm10051054.
6
Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer.应对前列腺癌免疫抑制微环境的新型组合方法。
Cancers (Basel). 2021 Mar 8;13(5):1145. doi: 10.3390/cancers13051145.
7
Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death.组蛋白 H3K27 去甲基酶抑制可使 Brachyury（TBXT）失活并促进脊索瘤细胞死亡。
Cancer Res. 2020 Oct 15;80(20):4540-4551. doi: 10.1158/0008-5472.CAN-20-1387. Epub 2020 Aug 27.
8
Inhibition Of Glycogen Synthase Kinase 3 Beta Suppresses The Growth And Survival Of Skull Base Chordoma Cells By Downregulating Brachyury Expression.抑制糖原合酶激酶3β通过下调短尾相关转录因子表达抑制颅底脊索瘤细胞的生长和存活。
Onco Targets Ther. 2019 Nov 18;12:9783-9791. doi: 10.2147/OTT.S218930. eCollection 2019.
9
Identification of a Subtype of Poorly Differentiated Invasive Ductal Carcinoma of the Breast Based on Vimentin and E-cadherin Expression.基于波形蛋白和E-钙黏蛋白表达鉴定乳腺低分化浸润性导管癌的一种亚型
Rev Bras Ginecol Obstet. 2018 Dec;40(12):779-786. doi: 10.1055/s-0038-1673700. Epub 2018 Oct 25.
10
The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy.循环肿瘤细胞与免疫系统之间的相互作用：从免疫逃逸到癌症免疫治疗
Diagnostics (Basel). 2018 Aug 30;8(3):59. doi: 10.3390/diagnostics8030059.
本文引用的文献
1
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
2
The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1α expression in breast cancer cells.Brachyury在诱导乳腺癌细胞上皮-间质转化（EMT）和缺氧诱导因子-1α（HIF-1α）表达中的潜在作用。
Biochem Biophys Res Commun. 2015 Nov 27;467(4):1083-9. doi: 10.1016/j.bbrc.2015.09.076. Epub 2015 Sep 21.
3
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.作为一种免疫疗法的、靶向三种肿瘤抗原的新型重组腺病毒疫苗组合的产生与分析。
Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181.
4
Adaptive Immune Resistance: How Cancer Protects from Immune Attack.适应性免疫抗性：癌症如何抵御免疫攻击。
Cancer Discov. 2015 Sep;5(9):915-9. doi: 10.1158/2159-8290.CD-15-0563. Epub 2015 Aug 13.
5
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.靶向转录因子 Brachyury 的酵母基治疗性癌症疫苗（GI-6301）的 I 期临床试验。
Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.
6
Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.核Brachyury表达在脊索瘤中一致，在生殖细胞肿瘤和小细胞癌中常见，而在其他癌和肉瘤中罕见：一项对5229例病例的免疫组织化学研究
Am J Surg Pathol. 2015 Oct;39(10):1305-12. doi: 10.1097/PAS.0000000000000462.
7
The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival.胚胎期的短尾（Brachyury）转录因子是胃肠道间质瘤侵袭性和预后不良的一种新型生物标志物。
Gastric Cancer. 2016 Apr;19(2):651-659. doi: 10.1007/s10120-015-0505-0. Epub 2015 May 21.
8
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.单药AZD1775（MK-1775），一种Wee1激酶抑制剂，用于难治性实体瘤患者的I期研究。
J Clin Oncol. 2015 Oct 20;33(30):3409-15. doi: 10.1200/JCO.2014.60.4009. Epub 2015 May 11.
9
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
10
Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.Brachyury对非小细胞肺癌上皮-间质转化及化疗敏感性的影响
Mol Med Rep. 2015 Jul;12(1):995-1001. doi: 10.3892/mmr.2015.3348. Epub 2015 Feb 13.
Zotero 插件